Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ CHINA RES POWER Tumbles ~7% as 1H Core Biz Profit Inches Up Only 0.1% w/ Reduced Interim DPS (AAStocks) +++ CHINA RESOURCES POWER Aktie -7,07%

VERTEX PHARMACEUTICALS Aktie

 >VRTX Aktienkurs 
337.5 EUR    -0.3%    (Tradegate)
Ask: 340.05 EUR / 45 Stück
Bid: 337.55 EUR / 45 Stück
Tagesumsatz: 7 Stück
Realtime Kurs von 8 bis 22 Uhr!
VRTX Aktie über LYNX handeln
>VRTX Performance
1 Woche: -0,1%
1 Monat: -14,5%
3 Monate: -14,7%
6 Monate: -26,2%
1 Jahr: -22,3%
laufendes Jahr: -12,8%
>VERTEX PHARMACEUTICALS Aktie
Name:  VERTEX PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US92532F1003 / 882807
Symbol/ Ticker:  VX1 (Frankfurt) / VRTX (NASDAQ)
Kürzel:  FRA:VX1, ETR:VX1, VX1:GR, NASDAQ:VRTX
Index:  S&P500, Nasdaq100
Webseite:  https://www.vrtx.com/
Profil:  Vertex Pharmaceuticals Inc. is a leading biotechno..
>Volltext..
Marktkapitalisierung:  85979.53 Mio. EUR
Unternehmenswert:  81852.22 Mio. EUR
Umsatz:  9778.72 Mio. EUR
EBITDA:  3918.83 Mio. EUR
Nettogewinn:  3121.75 Mio. EUR
Gewinn je Aktie:  12.13 EUR
Schulden:  1310.8 Mio. EUR
Liquide Mittel:  4275.5 Mio. EUR
Operativer Cashflow:  3300.94 Mio. EUR
Bargeldquote:  1.54
Umsatzwachstum:  0.37%
Gewinnwachstum:  -
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  2 Insider kauften innerhalb der letzten 30 Tage Aktien im Wert von 5.844.183 USD.
Suchwörter:  VERTEX PHARMACEUTICALS, VERTEX PHARMA, VRTX
Letzte Datenerhebung:  21.08.25
>VRTX Kennzahlen
Aktien/ Unternehmen:
Aktien: 256.39 Mio. St.
Frei handelbar: 99.68%
Rückkaufquote: 1.43%
Mitarbeiter: 6100
Umsatz/Mitarb.: 1.55 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 24.85%
Bewertung:
KGV: 28.22
KGV lG: 21.63
KUV: 8.85
KBV: 5.89
PEG-Ratio: -
EV/EBITDA: 20.89
Rentabilität:
Bruttomarge: 86.08%
Gewinnmarge: 31.92%
Operative Marge: 38.33%
Managementeffizenz:
Gesamtkaprendite: 16.47%
Eigenkaprendite: 22.77%
>VRTX Peer Group

Es sind 601 Aktien bekannt.
 
20.08.25 - 10:49
What′s Wrong With Vertex Pharmaceuticals Stock? (Fool)
 
Shares of the pharma company are down 17% in the past 12 months....
14.08.25 - 14:12
Vortex Energy meldet erfolgreiche Installation von ANT-Sensoren im Salzprojekt Robinsons River (IRW Press)
 
Vortex Energy erweitert das Untergrundbildgebungsverfahren auf dem Salzprojekt Robinsons River Vancouver, British Columbia, 14. August 2025 / IRW-Press / Vortex Energy Corp. (CSE: VRTX | OTC: VTECF |......
10.08.25 - 23:30
S&P 500 Healthcare Weighting At Multi-Decade Lows  (ZeroHedge)
 
S&P 500 Healthcare Weighting At Multi-Decade Lows  Earnings season has ended for large-cap biopharma stocks, with steep selloffs across many names as the healthcare sector's weighting in the S&P 500 falls to a multi-decade low. Pessimism is elevated across the sector amid the Trump administration's Most Favored Nation (MFN) pricing proposal for Medicaid and the prospect of pharmaceutical tariffs. A Goldman Sachs team led by Asad Haider told clients Friday that healthcare stocks face weak sector performance and mounting pessimism, as earnings season wrapped up last week.  Here are some of the highlights of the note titled "Global Healthcare: Pharmaceuticals: Friday Fodder: Slimmer Positioning Into The August Lull":  Earnings season ended with large selloffs in two key growth names: Vertex Pharmaceuticals (-20.6% on Aug. 4, pain program setback) and Eli Lilly And Co crshed the most since the DotCom era after underwhelming oral GLP-1 pill data.  This followed earlier 10% to...
08.08.25 - 02:01
Insiderhandel: Aufsichtsrat kauft Aktien von Vertex Pharmaceuticals im Wert von 1948415 USD (Insiderkauf)
 
Sachs, Bruce I. - Aufsichtsrat - Tag der Transaktion: 2025-08-06...
08.08.25 - 02:01
Insiderhandel: CEO & President kauft Aktien von Vertex Pharmaceuticals im Wert von 3895768 USD (Insiderkauf)
 
Kewalramani, Reshma - Vorstand - Tag der Transaktion: 2025-08-06...
06.08.25 - 11:12
7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip (Fool)
 
There's more good news than bad news for this big biotech stock....
05.08.25 - 19:00
VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal (Zacks)
 
Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal....
05.08.25 - 15:03
Vertex Pharma toppt Erwartungen – darum wird die Aktie trotzdem durchgereicht (Der Aktionaer)
 
Die Biotech-Gesellschaft Vertex Pharmaceuticals hat erneut starke Quartalszahlen vorgelegt. Die Amerikaner profitieren weiterhin von ihrer Ausnahmestellung im Bereich der Mukoviszidose-Medikamente. Allerdings wachsen die Zweifel daran, wie die Zukunft nach dem Auslauf der Patente der Mukoviszidose-Mittel aussehen soll....
05.08.25 - 10:36
Vertex Falls After FDA Doubts Broad Use of Chronic Pain Drug (Bloomberg)
 
Vertex Pharmaceuticals Inc. shares fell 15% after an experimental pain drug failed to benefit patients after surgery and US regulators said they didn't see a path forward for broad use of its pill in treating a chronic pain condition....
05.08.25 - 10:18
Vertex Pharmaceuticals stock falls as pain drug fails in phase 2 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.08.25 - 01:45
Selloff? What Selloff? Monday Market Rebound (Zacks)
 
Palantir is way up after reporting Q2 results Monday afternoon, while HIMS and VRTX are way off highs....
05.08.25 - 01:00
Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics (Zacks)
 
While the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....
04.08.25 - 23:18
Stocks making the biggest moves after hours: Palantir, Hims & Hers Health, Vertex Pharmaceuticals and more (CNBC)
 
These are the stocks posting the largest moves in extended trading....
04.08.25 - 22:06
Vertex Pharmaceuticals Non-GAAP EPS of $4.52 beats by $0.27, revenue of $2.96B beats by $50M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
04.08.25 - 12:54
Stock Market Today: US Stocks Likely To Open Higher Despite Weak Jobs Report—Palantir, Vertex Pharma In Focus (Benzinga)
 
US stock futures are up on Monday after ending Friday deep in the red, following a disappointing jobs report by Bureau of Labor Statistics. read more...
01.08.25 - 19:15
KBRA Assigns Preliminary Ratings to VRTX 2025-HQ (Business Wire)
 
NEW YORK--(BUSINESS WIRE)--#creditratingagency--KBRA announces the assignment of preliminary ratings to five classes of VRTX 2025-HQ, a CMBS single-borrower securitization. The collateral for the transaction is a $600 million portion of a $1.0 billion fixed rate, interest-only first lien mortgage loan. The fixed-rate loan has a five-year term and requires monthly interest-only payments based on an assumed interest rate of 6.25%. The loan is secured by the borrower's fee simple interest in Vertex HQ , two 15-story, Class-A, LEED Gold office tower containing 1.1 million sf. The building is located in the Seaport neighborhood of downtown Boston. The buildings were developed in 2013 as a built-to-suit corporate headquarters for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). KBRA performed a credit estimate on Vertex, and the results of the analysis indicated that Vertex has credit characteristics consistent with an entity with an investment grade rating. Vertex leases all of the office and lab space at ...
28.07.25 - 17:30
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
 
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
28.07.25 - 14:00
The 3 Things That Matter for Vertex Pharmaceuticals Now (Fool)
 
Some of these developments could improve the company's prospects....
24.07.25 - 11:01
brite(TM)-Plattform von XO Life: Digitale Therapiebegleitung für Menschen mit Mukoviszidose (News Aktuell)
 
XO Life GmbH: München (ots) - Vertex Pharmaceuticals, ein US-amerikanisches Pharmaunternehmen mit Fokus auf schwere Erkrankungen wie Mukoviszidose, Beta-Thalassämie und Sichelzellanämie, und XO Life, ein führendes Digital Health Scaleup geben ihre Kooperation ......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Nur übereilt bestimmt die Neigung sich. - Johann Wolfgang von Goethe
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!